Abstract:Current guidelines recommend inhalation therapy as the preferred route of drug administration for treating patients with chronic obstructive pulmonary disease (COPD). Inhalation devices consist of nebulizers and handheld inhalers, such as dry-powder inhalers (DPIs), pressurized metered-dose inhalers (pMDIs), and soft mist inhalers (SMIs). Although pMDIs, DPIs and SMIs may be appropriate for most patients with COPD, certain patient populations may have challenges with these devices. Patients who have cognitive, neuromuscular, or ventilatory impairments (and receive limited assistance from caregivers), as well as those with suboptimal peak inspiratory flow may not derive the full benefit from handheld inhalers. A considerable number of patients are not capable of producing a peak inspiratory flow rate to overcome the internal resistance of DPIs. Furthermore, patients may have difficulty coordinating inhalation with device actuation, which is required for pMDIs and SMIs. However, inhalation devices such as spacers and valved holding chambers can be used with pMDIs to increase the efficiency of aerosol delivery. Nebulized treatment provides patients with COPD an alternative administration route that avoids the need for inspiratory flow, manual dexterity, or complex hand-breath coordination. The recent approval of two nebulized long-acting muscarinic antagonists has added to the extensive range of nebulized therapies in COPD. Furthermore, with the availability of quieter and more portable nebulizer devices, nebulization may be a useful treatment option in the management of certain patient populations with COPD. The aim of this narrative review was to highlight recent updates and the treatment landscape in nebulized therapy and COPD. We first discuss the pathophysiology of patients with COPD and inhalation device considerations. Second, we review the updates on recently approved and newly marketed nebulized treatments, nebulized treatments currently in development, and technological advances in nebulizer devices. Finally, we discuss the current applications of nebulized therapy in patients with COPD.

Nebulized inhalation drug delivery: clinical applications and advancements in research

Inhaled drug delivery: Past, present, and future

Pulmonary delivery drugs:developments in nebulizers

Ultrasonic nebulization platforms for pulmonary drug delivery

Recent Advancement in Inhaled Nano-drug Delivery for Pulmonary, Nasal, and Nose-to-brain Diseases

Nano-Formulations for Pulmonary Delivery: Past, Present, and Future Perspectives

Nanocrystals based pulmonary inhalation delivery system: advance and challenge

Nanoparticle-Based Drug Delivery Systems in Inhaled Therapy: Improving Respiratory Medicine

Current progress on pulmonary drug delivery

Progress in the Application of Nano- and Micro-based Drug Delivery Systems in Pulmonary Drug Delivery

A Review of Non-Invasive Drug Delivery through Respiratory Routes

Dry Powder Inhalers: A Focus on Advancements in Novel Drug Delivery Systems

"Nano-in-Micro" Structured Dry Powder Inhalers for pulmonary delivery: advances and challenges

Pulmonary Drug Delivery Products and Clinical Applications

Clinical application and research progress of atomization inhalation therapy

A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review)

A path forward in the development of new aerosol drug delivery devices for pediatrics

The Role of Pulmonary Drug Delivery in Modern Therapeutics: An Overview

Single-use disposable dry powder inhalers for pulmonary drug delivery

Nebulized Therapies in COPD: Past, Present, and the Future

Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol